← Eichor
Study identifier: NCT05447923 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Addressing Disparities in Colorectal Cancer Screening in Black and Underserved Phoenix Communities

Condition: Colorectal Carcinoma  ·  Sponsor: Mayo Clinic

PhaseNA
Planned participants450
Who can joinAll sexes, 45 Years to no upper limit
Healthy volunteersYes

About this study

This clinical trial studies disparities involving colorectal cancer prevention and screening in Black and underserved communities in the Phoenix metropolitan area. The Black community is disproportionately impacted by colorectal cancer, with the highest rate of any racial/ethnic group in the United States. There are complex reasons behind these disparities, largely related to socioeconomic factors and healthcare access. Providing access to free, home-based fecal immunochemical testing (FIT), colorectal screening education, and appropriate follow-up to predominantly Black community-based organizations and underserved communities may help to close this gap.

This description comes directly from the study's public registry record.

Talk to the study team

Yahaira J. Parker  ·  480-574-3171  ·  Parker.Yahaira@mayo.edu

Clinical Trials Referral Office  ·  855-776-0015  ·  mayocliniccancerstudies@mayo.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Mayo Clinic in ArizonaScottsdale, Arizona, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05447923